Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 321 of 5804
-
Less fluid, fewer complications? trial tests new strategy in liver transplants
Disease control Recruiting nowThe goal of the REFIL-2 study is to evaluate the effectiveness of a low splanchnic blood volume restrictive fluid management strategy (a strategy that involves limiting fluid administration and prioritizing the use of medications that raise blood pressure during surgery, combined…
Phase: NA • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could 4 months of antiviral drugs be enough for CMV-Infected newborns?
Disease control Not yet recruitingTitle: Evaluation of Long-term Efficacy of 4-month versus 6-month Course Antiviral Therapy for Neurodevelopmental Impairment Caused by Congenital CMV Infection: A Multicenter, Randomized, Controlled, Non-inferiority Clinical Study 1\. Background and Rationale:Congenital cytomega…
Phase: PHASE4 • Sponsor: Hu Bofei • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New Low-Cost radiation therapy could make liver cancer treatment accessible for all
Disease control Not yet recruitingPrimary liver tumors, with hepatocellular carcinoma (HCC) accounting for 80%, represent 6% of global cancer incidence and 9% of global cancer-associated mortality.HCC remains the leading causes of cancer-related deaths worldwide, due to late diagnosis. Although local-stage liver …
Phase: PHASE1 • Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New weekly shot shows promise for major weight loss in obesity trial
Disease control Recruiting nowPhase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes)…
Phase: PHASE2 • Sponsor: Hudson Biotech • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
AI eye check could save your sight: new trial tests smart screening for diabetes patients
Diagnosis ENROLLING_BY_INVITATIONThis pragmatic clinical trial is being conducted to test the effectiveness of AI in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 4 primary care clinics. This is an autonomous AI-based screening to detect diabetic eye diseas…
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Diagnosis
Last updated Jun 27, 2026 12:26 UTC
-
New drug combo shows promise for rare lymphoma in Real-World study
Disease control Recruiting nowThe goal of this observational study is to evaluate how well brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (CHP) works and how safe it is when used as first-line treatment in adults with CD30-positive peripheral T-cell lymphoma in Spain during routine cli…
Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
App aims to stop depression before it starts: 9,000-person trial launched
Prevention Not yet recruitingObjective: To design, develop, and evaluate a personalized intervention for the universal prevention of depression and anxiety in the general population based on risk algorithms, ICTs, and decision support systems (DSS). Methods: A double-blind, parallel-group, randomized contro…
Phase: NA • Sponsor: The Mediterranean Institute for the Advance of Biotechnology and Health Research • Aim: Prevention
Last updated Jun 26, 2026 18:51 UTC
-
New hope for pancreatic cancer: targeted combo trial opens
Disease control Recruiting nowThis study is a Phase II clinical trial that plans to enroll 40 patients with borderline resectable pancreatic cancer harboring a KRAS G12D mutation, aiming to evaluate the efficacy of HRS-4642 in combination with Nimotuzumab and AG in borderline resectable pancreatic cancer. The…
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug cocktail aims to shrink kidney tumors after first treatment fails
Disease control Not yet recruitingThe primary objective is to evaluate the improvement in Objective Response Rate (ORR) achieved with Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) in combination with Lenvatinib or Axitinib, in patients with locally advanced or metastatic c…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could two new drugs boost chemo success in HER2-Low breast cancer?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if add SHR-A1811 and/or Adebrelimab on standard chemotherapy could further improve the pCR rate in HR+/HER2 low early stage breast cancer patients. It will also learn about the safety of these combination regimen. The main questions it …
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New CAR-T therapy targets two proteins to fight tough leukemia and lymphoma
Disease control Not yet recruitingThe purpose of this clinical trial is to evaluate the safety and efficacy of CAR1922T2 T-cell therapy in participants with relapsed/refractory B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Participants will receive a single infusion of CAR1922T2 T-cells and comp…
Phase: EARLY_PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New combo therapy targets hard-to-treat brain metastasis in lung cancer patients
Disease control Recruiting nowThe goal of this clinical trial is to explore the efficacy and safety of double-dose third-generation EGFR-TKI combined with bevacizumab and intrathecal chemotherapy in treating advanced non-small cell lung cancer (NSCLC) patients with leptomeningeal metastasis that progressed af…
Phase: NA • Sponsor: Second Affiliated Hospital of Nanchang University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to shrink esophageal tumors before surgery
Disease control Not yet recruitingThis study includes patients with resectable esophageal squamous cell carcinoma who will undergo local radiotherapy (PTV: 1.5Gy Bid, for 5 days), followed by neoadjuvant treatment with Serplulimab combined with cisplatin and paclitaxel for three cycles. Afterward, they will under…
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New pill aims to stop rare lymphoma from coming back
Disease control Recruiting nowThis is a multicenter, randomized, double-blind, phase III clinical study comprising two arms: a golidocitinib group and a placebo group. The study aimed to evaluate the antitumor efficacy and safety of golidocitinib in patients who had achieved a response after first-line system…
Phase: PHASE3 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug aims to stop deadly transplant complication
Disease control Not yet recruitingTo apply Ivarmacitinib for the prevention of acute graft-versus-host disease (aGVHD) in HLA haploidentical transplantation, the incidence of grade II-IV aGVHD after prevention, the incidence of primary graft failure, the rate of GVHD-free relapse-free survival (GRFS) (12 months),…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New oral drug shows promise against deadly lassa fever in west africa trial
Disease control TerminatedThis multicenter, randomized, open-label Phase 2 clinical trial evaluates the safety, tolerability, and virologic efficacy of ARN-75039, a novel oral antiviral, for treating Lassa fever in hospitalized adults in West Africa. The study is conducted within the INTEGRATE platform an…
Phase: PHASE2 • Sponsor: Arisan Therapeutics, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New pill shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis is a single-arm, open-label, multicenter Phase II clinical study designed to enroll 65 subjects with relapsed or refractory follicular lymphoma (EZH2 wild-type). The study procedures include a pre-screening phase, screening phase, treatment phase, and follow-up phase.Eligib…
Phase: PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill aims to strengthen hearts in genetic cardiomyopathy
Disease control Recruiting nowThe Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are…
Phase: PHASE2, PHASE3 • Sponsor: Kardigan, Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New transplant recipe targets tough leukemia
Disease control Recruiting nowThis is a prospective, single-arm clinical study. It aims to evaluate the effectiveness and safety of a conditioning regimen containing thiotepa (in combination with busulfan and fludarabine, with or without ATG) of allogeneic hematopoietic stem cell transplantation (allo-HSCT) i…
Phase: NA • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug ICP-332 aims to soothe stubborn hives when antihistamines fail
Disease control Recruiting nowThe purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines
Phase: PHASE2, PHASE3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC